Can I Take St. John's Wort with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and How Is It Cleared by the Body?

MK-677, also called ibutamoren, is an orally active, non-peptide agonist of the ghrelin receptor (GHSR-1a). It stimulates pulsatile growth hormone release from the pituitary without suppressing endogenous GH feedback. Merck originally developed it; it has never received FDA approval and remains a Schedule I candidate under proposed DEA rulemaking as of 2024.

Pharmacokinetics and CYP3A4 Involvement

Ibutamoren has an oral bioavailability of roughly 60 to 70% and a plasma half-life of approximately 24 hours in healthy adults, allowing once-daily dosing [1]. In vitro metabolic phenotyping data submitted during its IND development identified CYP3A4 as a primary metabolizing enzyme, placing ibutamoren in the same broad metabolic category as hundreds of other drugs cleared via this pathway [2].

CYP3A4 accounts for the metabolism of roughly 30 to 40% of all marketed drugs [3]. Any agent that induces CYP3A4 activity can meaningfully reduce the area under the concentration-time curve (AUC) of a co-administered CYP3A4 substrate.

Why Half-Life Matters Here

A 24-hour half-life means ibutamoren already clears relatively slowly. If CYP3A4 is induced, clearance accelerates and trough plasma concentrations fall. Because ibutamoren's GH-stimulating effect is concentration-dependent, a drop in trough levels translates directly into a blunted IGF-1 response, the primary biomarker used to monitor ibutamoren's efficacy [1].

How Does St. John's Wort Induce CYP3A4?

St. John's Wort (Hypericum perforatum) is one of the three most potent herbal CYP3A4 inducers identified in pharmacokinetic research, alongside rifampin and carbamazepine [4]. Its active constituent, hyperforin, binds the pregnane X receptor (PXR), a nuclear receptor that transcriptionally upregulates CYP3A4, CYP2C9, and the drug efflux transporter P-glycoprotein (P-gp, also called MDR1) [4].

The PXR-Hyperforin Mechanism

Hyperforin concentrations in standardized SJW extracts (typically 3 to 5% hyperforin) are sufficient to activate PXR at clinically relevant doses [5]. PXR activation drives CYP3A4 gene expression in both hepatocytes and enterocytes, meaning first-pass extraction of oral substrates increases at two anatomical sites simultaneously. For an orally dosed compound like ibutamoren, the enterocyte effect alone can reduce bioavailability before the drug even reaches portal circulation [5].

Magnitude of CYP3A4 Induction

Controlled pharmacokinetic studies have quantified SJW's induction power. In a landmark study, SJW (300 mg three times daily for 14 days) reduced the AUC of the CYP3A4 substrate midazolam by approximately 50 to 75% [6]. Alprazolam AUC fell by 54% in a separate controlled trial [7]. The FDA Drug Interaction Guidance for Industry classifies SJW as a strong CYP3A4 inducer based on its ability to reduce CYP3A4 substrate AUC by more than 80% in some contexts [8]. These are not trivial reductions.

P-glycoprotein Co-Induction

Beyond CYP3A4, SJW induces P-gp. P-gp is an efflux pump in intestinal epithelium that actively pumps absorbed drug back into the gut lumen. If ibutamoren is a P-gp substrate (not yet confirmed in published literature but pharmacologically plausible given its molecular weight and lipophilicity), simultaneous P-gp induction would compound the CYP3A4-driven reduction in bioavailability [4].

What Is the Clinical Significance of This Interaction?

The direct clinical consequence depends on why someone is using ibutamoren. The compound has been studied in at least three distinct populations, and the stakes of a reduced drug level differ across them.

Adults With GH Deficiency or Age-Related GH Decline

In a 24-week randomized trial (N=65) published in the Annals of Internal Medicine, ibutamoren at 25 mg daily significantly increased mean IGF-1 by 52% above baseline in elderly adults with low IGF-1 levels compared with placebo [9]. The authors noted that maintaining IGF-1 in the target range was tied to the therapeutic endpoint of improved body composition and bone density. A pharmacokinetic interaction reducing ibutamoren AUC by 50% or more could eliminate measurable IGF-1 benefit in this group [9].

Individuals Using Ibutamoren for Muscle or Body Composition

St. John's Wort is commonly used for mild-to-moderate depression. The overlap with people self-administering ibutamoren for body composition goals is not trivial, given SJW's prevalence: the 2022 National Health Interview Survey estimated approximately 4.4 million U.S. Adults used herbal mental health supplements, with SJW among the top five [10]. Reduced ibutamoren exposure in this group means reduced GH pulse amplitude and lower IGF-1, a direct counter to the intended effect.

Clinical Trial Participants

Anyone enrolled in an ongoing ibutamoren trial who begins SJW without disclosure may unblind their treatment arm or introduce a pharmacokinetic confounder that invalidates their pharmacodynamic data. Most trial informed consent documents list herbal CYP inducers as prohibited concomitant medications.

CYP3A4 Interaction Risk Tiering for Ibutamoren Users

The table below presents an original HealthRX clinical decision framework for ranking interaction severity when co-administering CYP3A4-active agents with ibutamoren. This was developed by the HealthRX medical team based on published CYP3A4 induction fold-change data and ibutamoren's known metabolic pathway.

| Agent | CYP3A4 Effect | Estimated Ibutamoren AUC Impact | Clinical Action | |---|---|---|---| | St. John's Wort (hyperforin-containing) | Strong inducer | Potentially 50 to 80% reduction | Avoid concurrent use | | Rifampin | Strong inducer | Potentially 70 to 90% reduction | Contraindicated with most CYP3A4 substrates | | Carbamazepine | Moderate-strong inducer | Potentially 40 to 60% reduction | Use with monitoring; consider dose adjustment | | Echinacea (short course) | Weak/transient inducer | Minimal (<20%) | Generally acceptable | | Grapefruit juice | Inhibitor (CYP3A4) | Increase in AUC possible | Monitor for adverse effects if combined | | No CYP-active supplement | Neutral | No change | Standard monitoring applies |

This framework is intended as a clinical aide, not a substitute for individualized prescriber guidance.

Onset and Washout: Timing the Interaction

Understanding the time course of CYP3A4 induction by SJW is necessary for advising patients who want to transition between regimens.

Onset of Induction

CYP3A4 induction by SJW is not immediate. Measurable increases in CYP3A4 activity appear within 3 to 5 days of regular SJW use, but maximal induction typically requires 10 to 14 days of consistent dosing [6]. This means a person who begins SJW while already taking ibutamoren will experience a progressive decline in ibutamoren plasma levels over approximately two weeks, not an abrupt drop on day one.

Reversal After Stopping SJW

CYP3A4 activity returns toward baseline within 7 to 14 days of stopping SJW, reflecting the time needed for CYP3A4 protein turnover [4]. A washout of at least 14 days is a conservative, clinically defensible interval before resuming ibutamoren if someone has been on SJW for more than a week.

The FDA's guidance on drug interactions specifically calls out SJW as requiring washout before initiating CYP3A4-sensitive substrates in sensitive populations [8]. Applying that same principle to ibutamoren is mechanistically sound.

Pharmacodynamic Considerations

The interaction is primarily pharmacokinetic, but pharmacodynamic overlap also deserves mention.

HPA Axis and Cortisol

St. John's Wort has demonstrated mild effects on hypothalamic-pituitary-adrenal (HPA) axis activity in some studies, possibly reducing cortisol reactivity [11]. Ibutamoren increases cortisol modestly, a recognized side effect documented in early Merck pharmacology data, because ghrelin receptor activation influences ACTH secretion [1]. Whether these directionally opposing cortisol effects interact meaningfully in practice is not known, but the signal warrants monitoring in people who are sensitive to cortisol fluctuations.

Sleep Architecture

Ibutamoren increases slow-wave sleep duration, an effect tied to its GH-releasing mechanism [12]. St. John's Wort may mildly suppress REM sleep in some users. Combining the two could produce unpredictable net effects on sleep architecture. Patients who started ibutamoren specifically to improve sleep quality should monitor subjective and objective sleep outcomes if SJW is co-administered.

What to Do If You Are Already Taking Both

Stopping SJW abruptly is generally safe; it does not require a taper for most users. The sequence below is the HealthRX medical team's recommended clinical approach.

Step 1: Confirm the SJW Product Contains Hyperforin

Low-hyperforin SJW extracts (standardized to <0.2% hyperforin) show significantly attenuated CYP3A4 induction in pharmacokinetic studies [13]. If the product label specifies a low-hyperforin standardization, the interaction risk is substantially lower. Products standardized to 3 to 5% hyperforin carry the full induction risk described above.

Step 2: Stop SJW and Allow a 14-Day Washout

Discontinue SJW. Allow 14 days before re-establishing a stable ibutamoren dose-response relationship. During this period, CYP3A4 activity normalizes and ibutamoren plasma levels will rise toward their uninduced steady state.

Step 3: Check Serum IGF-1 Before and After Washout

Serum IGF-1 is the most accessible clinical proxy for ibutamoren's pharmacodynamic effect. A baseline IGF-1 measured while both compounds were co-administered, followed by a repeat measurement 4 weeks after stopping SJW, will clarify how much the interaction suppressed the drug's effect. Age- and sex-adjusted reference ranges for IGF-1 are available via the Endocrine Society's clinical practice guidelines [14].

Step 4: If SJW Is Needed for Depression, Discuss Alternatives

If SJW was chosen for mild-to-moderate depression, a prescriber can evaluate whether a non-CYP3A4-inducing alternative is appropriate. SSRIs such as escitalopram or sertraline do not induce CYP3A4 and would not carry the same pharmacokinetic interaction with ibutamoren [15]. That decision requires individual clinical assessment and is outside the scope of self-management.

Who Should Avoid This Combination Entirely?

Several groups face the highest risk from the SJW-ibutamoren interaction.

People Using Ibutamoren Under Medical Supervision for GH Deficiency

If a physician has prescribed or recommended ibutamoren as part of a structured GH optimization protocol, adding SJW without disclosure is likely to undermine the monitored treatment plan. IGF-1 targets will appear not to be met, potentially prompting unnecessary dose escalation.

Clinical Trial Participants

Most CRO protocols for ibutamoren studies list herbal CYP inducers as exclusionary or prohibited medications. Participants who add SJW risk protocol violation and data invalidation.

Anyone Using High-Hyperforin SJW Products Concurrently With Any CYP3A4-Sensitive Drug

The interaction extends well beyond ibutamoren. The FDA issued a public health advisory in 2000 specifically warning that SJW causes clinically significant interactions with cyclosporine, antiretroviral protease inhibitors, digoxin, warfarin, theophylline, and oral contraceptives [16]. Ibutamoren users who are also taking any of these medications carry compounded risk.

Monitoring Parameters

For anyone who has been taking both and is now transitioning off SJW, the following monitoring approach is clinically appropriate.

Serum IGF-1 should be measured at baseline (on both compounds), at 4 weeks post-SJW discontinuation, and at 8 weeks. Fasting glucose and insulin deserve attention because ibutamoren causes dose-dependent insulin resistance in some users, an effect documented in a 2-year extension study in older adults (N=292) where fasting glucose increased by a mean of 0.3 mmol/L at 25 mg daily [17]. St. John's Wort has not been shown to meaningfully affect glucose metabolism, so this concern is ibutamoren-specific but worth monitoring during any pharmacokinetic change.

Sleep quality tracking via a validated instrument (such as the Pittsburgh Sleep Quality Index) is also reasonable if sleep was a primary indication for ibutamoren use.